News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company plans to enter the EU markets in FY22
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Subscribe To Our Newsletter & Stay Updated
